AUTHOR=Li Jiaxuan , Wu Xin , Tan Xin , Wang Shixin , Qu Ruisi , Wu Xiaofeng , Chen Zhouqing , Wang Zhong , Chen Gang 

TITLE=The efficacy and safety of anti-Aβ agents for delaying cognitive decline in Alzheimer’s disease: a meta-analysis

JOURNAL=Frontiers in Aging Neuroscience

VOLUME=Volume 15 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2023.1257973

DOI=10.3389/fnagi.2023.1257973

ISSN=1663-4365

ABSTRACT=Background: This meta-analysis evaluates the efficacy and safety of amyloid-β (Aβ) targeted therapies for delaying cognitive deterioration in Alzheimer's disease (AD). Methods: PubMed, EMBASE, the Cochrane Library, and ClinicalTrials.gov were systematically searched to identify relevant studies published before January 18, 2023. Results: We pooled 33,689 participants from 42 studies. The meta-analysis showed no difference between anti-Aβ drugs and placebo in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), and anti-Aβ drugs were associated with a high risk of adverse events (ADAS-Cog: MDs = -0.08 [-0.32 to 0.15], P = 0.4785; AEs: RR = 1.07 [1.02 to 1.11], P = 0.0014). Monoclonal antibodies outperformed the placebo in delaying cognitive deterioration as measured by ADAS-Cog, Clinical Dementia Rating-Sum of Boxes (CDR-SB), Mini-Mental State Examination (MMSE) and Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL), without increasing the risk of adverse events (ADAS-Cog: MDs = -0.55 [-0.89 to 0.